Federal antitrust regulators are eyeing big drugmaker Mylan’s EpiPen business, the company said Monday.
Mylan, in a statement, said the Federal Trade Commission asked it “months ago” for information about its anti-allergy EpiPen “as part of a preliminary investigation.”
The disclosure comes nearly five months after two United States senators asked the FTC to investigate whether Mylan violated antitrust laws to protect the auto-injector EpiPen from competition.
Those lawmakers’ interest in EpiPen in turn was sparked by consumer outrage over Mylan having raised the price of the device more than 500 percent in recent years, to more than $600 per two-pack.
“Mylan received an information request from the FTC months ago as part of a preliminary investigation,” said Mylan spokeswoman Nina Devlin on Monday.
“Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit,” Devlin said.
“We note that the epinephrine auto-injector market is and always has been competitive, with multiple products competing on the market since we acquired EpiPen Auto-Injector.”
“Further, Teva has had patent licenses to launch their proposed generic alternative to EpiPen Auto-Injector since June 2015, pending FDA approval, years prior to patent expiry,” Devlin said.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI